| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Picolamine does not have a defined specific biological target as it is primarily used as a chemical building block rather than a pharmacologically active compound. Its role in research is as a precursor for the synthesis of compounds that may target various biological pathways. The amino group and pyridine ring make it a versatile intermediate for medicinal chemistry.
|
|---|---|
| ln Vitro |
As a chemical intermediate, Picolamine is not evaluated for direct biological activity in cell-based assays. Its role in research is as a building block for the synthesis of pharmaceutical compounds and other organic molecules. The compound's reactivity makes it suitable for exploring novel compounds targeting diverse biological pathways. No direct in vitro pharmacological activity has been reported for this compound.
|
| ln Vivo |
As a chemical intermediate, Picolamine is not administered in vivo for pharmacological evaluation. Its applications are limited to chemical synthesis and medicinal chemistry research. The compound is used to prepare derivatives that may have biological activity. No direct in vivo pharmacological studies have been reported for this compound. It is used exclusively in laboratory synthesis and chemical research applications.
|
| Enzyme Assay |
As a chemical intermediate, Picolamine does not have established receptor binding assay protocols. Its chemical properties are characterized by standard analytical methods including NMR and HPLC. Physical properties: molecular weight 108.14 g/mol; molecular formula C6H8N2; IUPAC name: (Pyridin-3-yl)methanamine; synonyms: 3-(Aminomethyl)pyridine, 3-Picolylamine; solubility: DMSO: 100 mg/mL (924.73 mM); storage: argon filling. No specific enzyme or receptor binding assays are applicable.
|
| Cell Assay |
Cellular studies with Picolamine are not typically conducted as the compound is not a pharmacologically active agent. If used in cell-based research, it would be as a precursor for synthesizing test compounds rather than as the test compound itself. Standard cell culture protocols would apply if cellular effects were to be evaluated, including appropriate solvent controls and cytotoxicity assessment. No specific cellular activity has been reported.
|
| Animal Protocol |
In vivo studies are not conducted with Picolamine as it is a chemical intermediate rather than a drug candidate. Any in vivo evaluations would be performed on derivatives synthesized from this compound rather than on the compound itself. No animal model studies have been reported for this compound. It is used exclusively in laboratory synthesis and chemical research applications.
|
| ADME/Pharmacokinetics |
Picolamine has a molecular weight of 108.14 g/mol and a molecular formula of C6H8N2. IUPAC name: (Pyridin-3-yl)methanamine. Synonyms: 3-(Aminomethyl)pyridine, 3-Picolylamine, NSC 59706. Solubility: DMSO: 100 mg/mL (924.73 mM). Storage: argon filling. No pharmacokinetic data are available as it is not a drug candidate.
|
| Toxicity/Toxicokinetics |
No toxicology data are available for Picolamine as it is a chemical intermediate rather than a pharmaceutical compound. Standard safety precautions for handling amines should be followed. The compound is intended for laboratory use only and is not intended for human consumption or therapeutic use. Appropriate personal protective equipment should be used when handling this compound.
|
| Additional Infomation |
Picolamine is also known as 3-Picolylamine, 3-(Aminomethyl)pyridine, and 3-Pyridinemethanamine. It is a nitrogen-containing heterocyclic compound featuring an amino group attached to the pyridine ring. It can be used for the synthesis of active compounds and has potential applications in pharmaceutical development as a building block. No clinical trials or regulatory approvals have been reported. The compound is for research use only.
|
| Molecular Formula |
C6H8N2
|
|---|---|
| Molecular Weight |
108.14
|
| Exact Mass |
108.068
|
| CAS # |
3731-52-0
|
| PubChem CID |
31018
|
| Appearance |
Colorless to light yellow liquid（Density：1.062 g/cm3）
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
226.0±0.0 °C at 760 mmHg
|
| Melting Point |
−21 °C(lit.)
|
| Flash Point |
100.6±0.0 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.552
|
| LogP |
-0.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
8
|
| Complexity |
63.5
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N([H])([H])C([H])([H])C1=C([H])N=C([H])C([H])=C1[H]
|
| InChi Key |
HDOUGSFASVGDCS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H8N2/c7-4-6-2-1-3-8-5-6/h1-3,5H,4,7H2
|
| Chemical Name |
pyridin-3-ylmethanamine
|
| Synonyms |
NSC-59706; NSC 59706; Picolamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~924.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.2473 mL | 46.2364 mL | 92.4727 mL | |
| 5 mM | 1.8495 mL | 9.2473 mL | 18.4945 mL | |
| 10 mM | 0.9247 mL | 4.6236 mL | 9.2473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
